;PMID: 11102958
;source_file_725.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..33] = [t:0..33]
;1)sentence:[e:38..106] = [t:38..106]
;2)section:[e:110..164] = [t:110..164]
;3)section:[e:168..291] = [t:168..291]
;4)sentence:[e:295..306] = [t:295..306]
;5)sentence:[e:307..448] = [t:307..448]
;6)sentence:[e:449..611] = [t:449..611]
;7)sentence:[e:613..758] = [t:613..758]
;8)sentence:[e:760..938] = [t:760..938]
;9)sentence:[e:939..1083] = [t:939..1083]
;10)sentence:[e:1084..1218] = [t:1084..1218]
;11)sentence:[e:1219..1227] = [t:1219..1227]
;12)sentence:[e:1229..1568] = [t:1229..1568]
;13)sentence:[e:1569..1577] = [t:1569..1577]
;14)sentence:[e:1578..1666] = [t:1578..1666]
;15)sentence:[e:1667..1850] = [t:1667..1850]
;16)sentence:[e:1852..1864] = [t:1852..1864]
;17)sentence:[e:1865..2014] = [t:1865..2014]
;18)sentence:[e:2015..2196] = [t:2015..2196]
;19)sentence:[e:2197..2306] = [t:2197..2306]
;20)section:[e:2307..2338] = [t:2307..2338]
;21)section:[e:2342..2387] = [t:2342..2387]

;section 0 Span:0..33
;Prostate  2000 Dec 1;45(4):323-34
(SEC
  (FRAG (IN:[0..8] Prostate) (CD:[10..14] 2000) (.:[15..18] Dec)
        (CD:[19..24] 1;45-LRB-) (CD:[24..26] 4-RRB-) (CD:[26..30] :323)
        (::[30..31] -) (CD:[31..33] 34)))

;sentence 1 Span:38..106
;Detection and analysis of beta-catenin mutations in prostate cancer.
;[64..76]:gene-rna:"beta-catenin"
;[90..105]:malignancy:"prostate cancer"
(SENT
  (NP-HLN
    (NP (NN:[38..47] Detection) (CC:[48..51] and) (NN:[52..60] analysis))
    (PP (IN:[61..63] of)
      (NP
        (NP (NN:[64..76] beta-catenin) (NNS:[77..86] mutations))
        (PP (IN:[87..89] in)
          (NP (NN:[90..98] prostate) (NN:[99..105] cancer)))))
    (.:[105..106] .)))

;section 2 Span:110..164
;Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB.
(SEC
  (FRAG (NNP:[110..117] Chesire) (NNP:[118..120] DR) (,:[120..121] ,)
        (NNP:[122..127] Ewing) (NNP:[128..130] CM) (,:[130..131] ,)
        (NNP:[132..141] Sauvageot) (NNP:[142..144] J,) (NNP:[145..149] Bova)
        (NNP:[150..152] GS) (,:[152..153] ,) (NNP:[154..160] Isaacs)
        (NNP:[161..164] WB.)))

;section 3 Span:168..291
;Brady Urological Institute, Research Laboratories, The Johns Hopkins Medical 
;Institutions, Baltimore, Maryland 21287, USA.
(SEC
  (FRAG (NNP:[168..173] Brady) (NNP:[174..184] Urological)
        (NNP:[185..194] Institute) (,:[194..195] ,) (NNP:[196..204] Research)
        (NNP:[205..217] Laboratories) (,:[217..218] ,) (DT:[219..222] The)
        (NNP:[223..228] Johns) (NNP:[229..236] Hopkins) (NNP:[237..244] Medical)
        (NNP:[246..258] Institutions) (,:[258..259] ,)
        (NNP:[260..269] Baltimore) (,:[269..270] ,) (NNP:[271..279] Maryland)
        (VBZ:[280..285] 21287) (NNP:[285..286] ,) (NNP:[287..290] USA)
        (.:[290..291] .)))

;sentence 4 Span:295..306
;BACKGROUND:
(SENT
  (NP (NN:[295..305] BACKGROUND) (::[305..306] :)))

;sentence 5 Span:307..448
;E-cadherin and alpha-catenin are components of adherens junctions  which
;mediate calcium-dependent, cell-cell adhesion in a homotypic manner.
;[307..317]:gene-protein:"E-cadherin"
;[322..335]:gene-protein:"alpha-catenin"
(SENT
  (S
    (NP-SBJ (NN:[307..317] E-cadherin) (CC:[318..321] and)
            (NN:[322..335] alpha-catenin))
    (VP (VBP:[336..339] are)
      (NP-PRD
        (NP (NNS:[340..350] components))
        (PP (IN:[351..353] of)
          (NP
            (NP (NNS:[354..362] adherens) (NNS:[363..372] junctions))
            (SBAR
              (WHNP-1 (WDT:[374..379] which))
              (S
                (NP-SBJ-1 (-NONE-:[379..379] *T*))
                (VP (VBP:[380..387] mediate)
                  (NP
                    (ADJP (NN:[388..395] calcium) (HYPH:[395..396] -)
                          (JJ:[396..405] dependent))
                    (,:[405..406] ,)
                    (ADJP (NN:[407..411] cell) (HYPH:[411..412] -)
                          (NN:[412..416] cell))
                    (NN:[417..425] adhesion))
                  (PP-MNR (IN:[426..428] in)
                    (NP (DT:[429..430] a) (JJ:[431..440] homotypic)
                        (NN:[441..447] manner))))))))))
    (.:[447..448] .)))

;sentence 6 Span:449..611
;Both  these molecules have been defined as useful tumor markers as their
;altered  expression correlates with increased tumor aggressiveness and
;dedifferentiation.
(SENT
  (S
    (NP-SBJ-3 (PDT:[449..453] Both) (DT:[455..460] these)
              (NNS:[461..470] molecules))
    (VP (VBP:[471..475] have)
      (VP (VBN:[476..480] been)
        (VP (VBN:[481..488] defined)
          (NP-3 (-NONE-:[488..488] *))
          (PP-CLR (IN:[489..491] as)
            (NP (JJ:[492..498] useful) (NN:[499..504] tumor)
                (NNS:[505..512] markers)))
          (SBAR-ADV (IN:[513..515] as)
            (S
              (NP-SBJ (PRP$:[516..521] their) (VBN:[522..529] altered)
                      (NN:[531..541] expression))
              (VP (VBZ:[542..552] correlates)
                (PP-CLR (IN:[553..557] with)
                  (NP
                    (NP
                      (ADJP-2 (VBN:[558..567] increased))
                      (NML-1 (NN:[568..573] tumor))
                      (NN:[574..588] aggressiveness))
                    (CC:[589..592] and)
                    (NP
                      (ADJP-2 (-NONE-:[592..592] *P*))
                      (NML-1 (-NONE-:[592..592] *P*))
                      (NN:[593..610] dedifferentiation))))))))))
    (.:[610..611] .)))

;sentence 7 Span:613..758
;More recently, alterations of a third component of adherens junctions, 
;beta-catenin, have been observed to play a role in several human cancers.
;[685..697]:gene-protein:"beta-catenin"
(SENT
  (S
    (ADVP-TMP (RBR:[613..617] More) (RB:[618..626] recently))
    (,:[626..627] ,)
    (NP-SBJ-1
      (NP (NNS:[628..639] alterations))
      (PP (IN:[640..642] of)
        (NP
          (NP
            (NP (DT:[643..644] a) (JJ:[645..650] third)
                (NN:[651..660] component))
            (PP (IN:[661..663] of)
              (NP (NNS:[664..672] adherens) (NNS:[673..682] junctions))))
          (,:[682..683] ,)
          (NP (NN:[685..697] beta-catenin)))))
    (,:[697..698] ,)
    (VP (VBP:[699..703] have)
      (VP (VBN:[704..708] been)
        (VP (VBN:[709..717] observed)
          (NP-1 (-NONE-:[717..717] *))
          (S
            (NP-SBJ (-NONE-:[717..717] *))
            (VP (TO:[718..720] to)
              (VP (VB:[721..725] play)
                (NP (DT:[726..727] a) (NN:[728..732] role))
                (PP (IN:[733..735] in)
                  (NP (JJ:[736..743] several) (JJ:[744..749] human)
                      (NNS:[750..757] cancers)))))))))
    (.:[757..758] .)))

;sentence 8 Span:760..938
;Dysregulation of beta-catenin, either by direct mutation or by defects in 
;interacting pathways/regulators, can result in its cytoplasmic accumulation
;and  nuclear translocation.
;[777..789]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[760..773] Dysregulation))
      (PP (IN:[774..776] of)
        (NP (NN:[777..789] beta-catenin))))
    (,:[789..790] ,)
    (PP-MNR (CC:[791..797] either)
      (PP (IN:[798..800] by)
        (NP (JJ:[801..807] direct) (NN:[808..816] mutation)))
      (CC:[817..819] or)
      (PP (IN:[820..822] by)
        (NP
          (NP (NNS:[823..830] defects))
          (PP (IN:[831..833] in)
            (NP (VBG:[835..846] interacting) (NNS:[847..855] pathways)
                (SYM:[855..856] /) (NNS:[856..866] regulators))))))
    (,:[866..867] ,)
    (VP (MD:[868..871] can)
      (VP (VB:[872..878] result)
        (PP-CLR (IN:[879..881] in)
          (NP (PRP$:[882..885] its)
            (NML
              (NML (JJ:[886..897] cytoplasmic) (NN:[898..910] accumulation))
              (CC:[911..914] and)
              (NML (JJ:[916..923] nuclear) (NN:[924..937] translocation)))))))
    (.:[937..938] .)))

;sentence 9 Span:939..1083
;In the nucleus, beta-catenin forms a transcriptional  complex capable of
;upregulating target genes, many of which encode proliferative  factors.
;[955..967]:gene-protein:"beta-catenin"
(SENT
  (S
    (PP-LOC (IN:[939..941] In)
      (NP (DT:[942..945] the) (NN:[946..953] nucleus)))
    (,:[953..954] ,)
    (NP-SBJ (NN:[955..967] beta-catenin))
    (VP (VBZ:[968..973] forms)
      (NP
        (NP (DT:[974..975] a) (JJ:[976..991] transcriptional)
            (NN:[993..1000] complex))
        (ADJP (JJ:[1001..1008] capable)
          (PP (IN:[1009..1011] of)
            (NP
              (NP (VBG:[1012..1024] upregulating) (NN:[1025..1031] target)
                  (NNS:[1032..1037] genes))
              (,:[1037..1038] ,)
              (SBAR
                (WHNP-1
                  (WHNP (JJ:[1039..1043] many))
                  (PP (IN:[1044..1046] of)
                    (WHNP (WDT:[1047..1052] which))))
                (S
                  (NP-SBJ-1 (-NONE-:[1052..1052] *T*))
                  (VP (VBP:[1053..1059] encode)
                    (NP (JJ:[1060..1073] proliferative)
                        (NNS:[1075..1082] factors))))))))))
    (.:[1082..1083] .)))

;sentence 10 Span:1084..1218
;Given its oncogenic activity and connection to human cancer, we  examined the
;beta-catenin gene and its expression in prostate cancer.
;[1162..1174]:gene-rna:"beta-catenin"
;[1202..1217]:malignancy:"prostate cancer"
(SENT
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[1084..1084] *))
      (VP (VBN:[1084..1089] Given)
        (NP (PRP$:[1090..1093] its)
          (NML
            (NML (JJ:[1094..1103] oncogenic) (NN:[1104..1112] activity))
            (CC:[1113..1116] and)
            (NML
              (NML (NN:[1117..1127] connection))
              (PP (TO:[1128..1130] to)
                (NP (JJ:[1131..1136] human) (NN:[1137..1143] cancer))))))))
    (,:[1143..1144] ,)
    (NP-SBJ (PRP:[1145..1147] we))
    (VP (VBD:[1149..1157] examined)
      (NP
        (NP (DT:[1158..1161] the) (NN:[1162..1174] beta-catenin)
            (NN:[1175..1179] gene))
        (CC:[1180..1183] and)
        (NP
          (NP (PRP$:[1184..1187] its) (NN:[1188..1198] expression))
          (PP (IN:[1199..1201] in)
            (NP (NN:[1202..1210] prostate) (NN:[1211..1217] cancer))))))
    (.:[1217..1218] .)))

;sentence 11 Span:1219..1227
;METHODS:
(SENT
  (NP (NNS:[1219..1226] METHODS) (::[1226..1227] :)))

;sentence 12 Span:1229..1568
;By single-stranded conformational polymorphism (SSCP) and DNA sequencing 
;analyses, we screened exon 3 of beta-catenin from a panel of 81 primary
;tumors  obtained at radical prostatectomy, 22 lymph node metastases from
;untreated  patients, and a unique set of 61 metastatic tissues from 19
;patients who died of  hormone-refractory disease.
;[1325..1331]:variation-location:"exon 3"
;[1335..1347]:gene-rna:"beta-catenin"
;[1367..1381]:malignancy:"primary tumors"
;[1421..1442]:malignancy:"lymph node metastases"
;[1492..1510]:malignancy:"metastatic tissues"
(SENT
  (S
    (PP-MNR (IN:[1229..1231] By)
      (NP
        (NML
          (NML
            (NML
              (NML (JJ:[1232..1238] single) (HYPH:[1238..1239] -)
                   (JJ:[1239..1247] stranded))
              (JJ:[1248..1262] conformational) (NN:[1263..1275] polymorphism))
            (NML (-LRB-:[1276..1277] -LRB-) (NN:[1277..1281] SSCP)
                 (-RRB-:[1281..1282] -RRB-)))
          (CC:[1283..1286] and)
          (NML (NN:[1287..1290] DNA) (NN:[1291..1301] sequencing)))
        (NNS:[1303..1311] analyses)))
    (,:[1311..1312] ,)
    (NP-SBJ (PRP:[1313..1315] we))
    (VP (VBD:[1316..1324] screened)
      (NP
        (NP (NN:[1325..1329] exon) (CD:[1330..1331] 3))
        (PP (IN:[1332..1334] of)
          (NP (NN:[1335..1347] beta-catenin))))
      (PP (IN:[1348..1352] from)
        (NP
          (NP (DT:[1353..1354] a) (NN:[1355..1360] panel))
          (PP (IN:[1361..1363] of)
            (NP
              (NP
                (NP (CD:[1364..1366] 81)
                   (JJ:[1367..1374] primary) (NNS:[1375..1381] tumors))
                (VP (VBN:[1383..1391] obtained)
                  (NP (-NONE-:[1391..1391] *))
                  (PP-TMP (IN:[1392..1394] at)
                    (NP (JJ:[1395..1402] radical)
                        (NN:[1403..1416] prostatectomy)))))
              (,:[1416..1417] ,)
              (NP
                (NP (CD:[1418..1420] 22)
                  
                  (NML (NN:[1421..1426] lymph) (NN:[1427..1431] node))
                  (NNS:[1432..1442] metastases))
                (PP (IN:[1443..1447] from)
                  (NP (JJ:[1448..1457] untreated) (NNS:[1459..1467] patients))))
              (,:[1467..1468] ,) (CC:[1469..1472] and)
              (NP
                (NP (DT:[1473..1474] a) (JJ:[1475..1481] unique)
                    (NN:[1482..1485] set))
                (PP (IN:[1486..1488] of)
                  (NP
                    (NP (CD:[1489..1491] 61)
                       (JJ:[1492..1502] metastatic) (NNS:[1503..1510] tissues))
                    (PP (IN:[1511..1515] from)
                      (NP
                        (NP (CD:[1516..1518] 19) (NNS:[1519..1527] patients))
                        (SBAR
                          (WHNP-1 (WP:[1528..1531] who))
                          (S
                            (NP-SBJ-1 (-NONE-:[1531..1531] *T*))
                            (VP (VBD:[1532..1536] died)
                              (PP-CLR (IN:[1537..1539] of)
                                (NP
                                  (ADJP (NN:[1541..1548] hormone)
                                        (HYPH:[1548..1549] -)
                                        (JJ:[1549..1559] refractory))
                                  (NN:[1560..1567] disease))))))))))))))))
    (.:[1567..1568] .)))

;sentence 13 Span:1569..1577
;RESULTS:
(SENT
  (NP (NNS:[1569..1576] RESULTS) (::[1576..1577] :)))

;sentence 14 Span:1578..1666
;We found putative activating mutations  (missense and deletion) at a rate of
;5% (7/138).
;[1607..1616]:variation-event:"mutations"
;[1619..1627]:variation-type:"missense"
;[1632..1640]:variation-type:"deletion"
(SENT
  (S
    (NP-SBJ (PRP:[1578..1580] We))
    (VP (VBD:[1581..1586] found)
      (NP (JJ:[1587..1595] putative) (VBG:[1596..1606] activating)
          (NNS:[1607..1616] mutations)
        (PRN (-LRB-:[1618..1619] -LRB-)
          (NP (JJ:[1619..1627] missense) (CC:[1628..1631] and)
              (NN:[1632..1640] deletion))
          (-RRB-:[1640..1641] -RRB-)))
      (PP (IN:[1642..1644] at)
        (NP
          (NP (DT:[1645..1646] a) (NN:[1647..1651] rate))
          (PP (IN:[1652..1654] of)
            (NP (CD:[1655..1656] 5) (NN:[1656..1657] %)
              (PRN (-LRB-:[1658..1659] -LRB-)
                (NP
                  (NP (CD:[1659..1660] 7))
                  (PP (SYM:[1660..1661] /)
                    (NP (CD:[1661..1664] 138))))
                (-RRB-:[1664..1665] -RRB-)))))))
    (.:[1665..1666] .)))

;sentence 15 Span:1667..1850
;One patient had the same 72  base pair deletion in each of nine separate
;metastases examined, indicating that  this change was associated with a
;clonal population of metastatic cells.
;[1696..1714]:variation-type:"base pair deletion"
;[1740..1750]:malignancy:"metastases"
;[1812..1849]:malignancy:"clonal population of metastatic cells"
(SENT
  (S
    (NP-SBJ (CD:[1667..1670] One) (NN:[1671..1678] patient))
    (VP (VBD:[1679..1682] had)
      (NP (DT:[1683..1686] the) (JJ:[1687..1691] same)
        (NML (CD:[1692..1694] 72) (NN:[1696..1700] base) (NN:[1701..1705] pair))
        (NN:[1706..1714] deletion))
      (PP-LOC (IN:[1715..1717] in)
        (NP
          (NP (DT:[1718..1722] each))
          (PP (IN:[1723..1725] of)
            (NP
              (NP (CD:[1726..1730] nine) (JJ:[1731..1739] separate)
                  (NNS:[1740..1750] metastases))
              (VP (VBN:[1751..1759] examined)
                (NP (-NONE-:[1759..1759] *)))))))
      (,:[1759..1760] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1760..1760] *))
        (VP (VBG:[1761..1771] indicating)
          (SBAR (IN:[1772..1776] that)
            (S
              (NP-SBJ-1 (DT:[1778..1782] this) (NN:[1783..1789] change))
              (VP (VBD:[1790..1793] was)
                (VP (VBN:[1794..1804] associated)
                  (NP-1 (-NONE-:[1804..1804] *))
                  (PP-CLR (IN:[1805..1809] with)
                    (NP
                      (NP (DT:[1810..1811] a) (JJ:[1812..1818] clonal)
                          (NN:[1819..1829] population))
                      (PP (IN:[1830..1832] of)
                        (NP (JJ:[1833..1843] metastatic)
                            (NNS:[1844..1849] cells))))))))))))
    (.:[1849..1850] .)))

;sentence 16 Span:1852..1864
;CONCLUSIONS:
(SENT
  (NP (NNS:[1852..1863] CONCLUSIONS) (::[1863..1864] :)))

;sentence 17 Span:1865..2014
;Immunohistological staining of mutation-positive tumors  demonstrated
;beta-catenin accumulation and nuclear localization in a  heterogeneous
;fashion.
;[1896..1920]:malignancy:"mutation-positive tumors"
;[1935..1947]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1865..1883] Immunohistological) (NN:[1884..1892] staining))
      (PP (IN:[1893..1895] of)
        (NP
          (NML (NN:[1896..1904] mutation) (HYPH:[1904..1905] -)
               (JJ:[1905..1913] positive))
          (NNS:[1914..1920] tumors))))
    (VP (VBD:[1922..1934] demonstrated)
      (NP
        (NP
          (NP (NN:[1935..1947] beta-catenin) (NN:[1948..1960] accumulation))
          (CC:[1961..1964] and)
          (NP (JJ:[1965..1972] nuclear) (NN:[1973..1985] localization)))
        (PP (IN:[1986..1988] in)
          (NP (DT:[1989..1990] a) (JJ:[1992..2005] heterogeneous)
              (NN:[2006..2013] fashion)))))
    (.:[2013..2014] .)))

;sentence 18 Span:2015..2196
;Consistent with this in vivo finding, our in vitro  analyses demonstrate that
;certain mutations can result in increased beta-catenin  nuclear activity in
;prostate cancer cell lines.
;[2101..2110]:variation-event:"mutations"
;[2135..2147]:gene-protein:"beta-catenin"
;[2169..2195]:malignancy:"prostate cancer cell lines"
(SENT
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[2015..2015] *))
      (ADJP-PRD (JJ:[2015..2025] Consistent)
        (PP (IN:[2026..2030] with)
          (NP (DT:[2031..2035] this)
            (ADJP (FW:[2036..2038] in) (FW:[2039..2043] vivo))
            (NN:[2044..2051] finding)))))
    (,:[2051..2052] ,)
    (NP-SBJ (PRP$:[2053..2056] our)
      (ADJP (FW:[2057..2059] in) (FW:[2060..2065] vitro))
      (NNS:[2067..2075] analyses))
    (VP (VBP:[2076..2087] demonstrate)
      (SBAR (IN:[2088..2092] that)
        (S
          (NP-SBJ (JJ:[2093..2100] certain) (NNS:[2101..2110] mutations))
          (VP (MD:[2111..2114] can)
            (VP (VB:[2115..2121] result)
              (PP-CLR (IN:[2122..2124] in)
                (NP
                  (NP (VBN:[2125..2134] increased)
                      (NN:[2135..2147] beta-catenin) (JJ:[2149..2156] nuclear)
                      (NN:[2157..2165] activity))
                  (PP (IN:[2166..2168] in)
                    (NP (NN:[2169..2177] prostate) (NN:[2178..2184] cancer)
                        (NN:[2185..2189] cell) (NNS:[2190..2195] lines))))))))))
    (.:[2195..2196] .)))

;sentence 19 Span:2197..2306
;These data implicate the  beta-catenin signaling pathway in the development
;of a subset of prostate  cancers.
;[2223..2235]:gene-protein:"beta-catenin"
;[2288..2305]:malignancy:"prostate  cancers"
(SENT
  (S
    (NP-SBJ (DT:[2197..2202] These) (NNS:[2203..2207] data))
    (VP (VBP:[2208..2217] implicate)
      (NP (DT:[2218..2221] the) (NN:[2223..2235] beta-catenin)
          (NN:[2236..2245] signaling) (NN:[2246..2253] pathway))
      (PP (IN:[2254..2256] in)
        (NP
          (NP (DT:[2257..2260] the) (NN:[2261..2272] development))
          (PP (IN:[2273..2275] of)
            (NP
              (NP (DT:[2276..2277] a) (NN:[2278..2284] subset))
              (PP (IN:[2285..2287] of)
                (NP (NN:[2288..2296] prostate) (NNS:[2298..2305] cancers))))))))
    (.:[2305..2306] .)))

;section 20 Span:2307..2338
;Copyright 2000 Wiley-Liss, Inc.
(SEC
  (FRAG (NN:[2307..2316] Copyright) (CD:[2317..2321] 2000)
        (NNP:[2322..2327] Wiley) (HYPH:[2327..2328] -) (NNP:[2328..2332] Liss)
        (,:[2332..2333] ,) (NNP:[2334..2338] Inc.)))

;section 21 Span:2342..2387
;PMID: 11102958 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2342..2346] PMID) (::[2346..2347] :) (CD:[2348..2356] 11102958)
        (NN:[2357..2358] -LSB-) (NNP:[2358..2364] PubMed) (::[2365..2366] -)
        (NN:[2367..2374] indexed) (IN:[2375..2378] for)
        (NNP:[2379..2387] MEDLINE-RSB-)))
